DATA PRESENTED AT THE 2022 AMERICAN ACADEMY OF OPTOMETRY MEETINGMEIBOMIAN GLAND FUNCTION IMPROVES BY 63% AND DRY EYE SYMPTOMS REDUCED...
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a...
Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company...
The Company will Provide an Overview of its Immune Checkpoint Enhancer (ICE) Platform Clinical Proof-of-Concept Data from its First Generation...
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Company also announces that Julia Haller, MD, is stepping down from its Board of DirectorsNEW YORK, Dec. 08, 2022 (GLOBE...
MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for...
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion® proprietary antimicrobial intellectual property (IP), accelerating the product development pipeline for...
Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in vitroFirst-in-human studies anticipated to begin...
Conference Call to be Held on December 14th at 11:00 a.m. Eastern TimeHOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius...
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...
Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics SYDNEY, AUSTRALIA, Dec. 08,...
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic CancerMIRAMAR, Fla., Dec. 08, 2022...
- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with...
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial...
Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score Strongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will...
- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses -- Continued focus on development...
Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory ProgressHINGHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:...